Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...